Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to
assemble and peer-review its pathway modules. The integration of ORCID within Reactome
enables us to meet a key challenge with authoring, curating and reviewing biological
information by incentivizing and crediting the external experts that contribute their
expertise and time to the Reactome curation process. More information is available at
ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please
forward this information to us and we will update your Reactome pathway records.
Details on Person Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations
| Class:Id | LiteratureReference:9650849 |
|---|
| _displayName | Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations |
|---|
| _timestamp | 2019-06-24 10:43:04 |
|---|
| author | [Person:9650829] Suzawa, Ken
[Person:9650833] Toyooka, Shinichi
[Person:9650834] Sakaguchi, Masakiyo
[Person:9650837] Morita, Mizuki
[Person:9650835] Yamamoto, Hiromasa
[Person:9650844] Tomida, Shuta
[Person:9650850] Ohtsuka, Tomoaki
[Person:9650848] Watanabe, Mototsugu
[Person:9650852] Hashida, Shinsuke
[Person:9650840] Maki, Yuho
[Person:9650839] Soh, Junichi
[Person:9650842] Asano, Hiroaki
[Person:9650838] Tsukuda, Kazunori
[Person:9650843] Miyoshi, Shinichiro |
|---|
| created | [InstanceEdit:9650845] Orlic-Milacic, Marija, 2019-06-24 |
|---|
| journal | Cancer Sci. |
|---|
| pages | 45-52 |
|---|
| pubMedIdentifier | 26545934 |
|---|
| title | Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations |
|---|
| volume | 107 |
|---|
| year | 2016 |
|---|
| (literatureReference) | [Summation:9664919] Many EGFR-binding ERBB2 KD mutants were shown to activate PI...
[Summation:9664930] For the following EGFR-binding ERBB2 KD mutants that activat...
[Summation:9664945] For the following EGFR-binding ERBB2 KD mutants that were sh...
[Reaction:9664567] ERBB2 KD mutants heterodimerize [Homo sapiens]
[Reaction:9664588] ERBB2 KD mutants trans-autophosphorylate [Homo sapiens]
[Reaction:9664918] Phosphorylated heterodimers of ERBB2 KD mutants and EGFR bind GRB2:GAB1 [Homo sapiens]
[Reaction:9664933] Phosphorylated heterodimers of ERBB2 KD mutants and EGFR, in complex with GRB2:GAB1, bind PI3K [Homo sapiens]
[Reaction:9664940] PI3K bound to phosphorylated heterodimers of ERBB2 KD mutants and EGFR converts PIP2 to PIP3 [Homo sapiens]
[Reaction:9664950] Phosphorylated heterodimers of ERBB2 KD mutants bind SHC1 [Homo sapiens]
[Reaction:9664976] Phosphorylated heterodimers of ERBB2 KD mutants phosphorylate SHC1 [Homo sapiens] |
|---|
|
[Change default viewing format]
|
No pathways have been reviewed or authored by Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations (9650849)
